Medifast posted a loss of $0.28 per share, outpacing the consensus forecast of $0.66, while revenue fell 27.6% to $76.4 million. The earnings beat highlights improving coach productivity, yet the sharp revenue drop underscores ongoing market pressure on its weight‑loss platform, signalling volatility for investors.

Key Highlights

  • Revenue dropped 27.6% to $76.4 million, while revenue per active earning coach rose 41% to $6,529.
  • Gross profit fell 30.3% to $53.4 million, and gross margin slipped to 69.9% from 72.6%.
  • Operating loss widened to $4.3 million, representing 5.7% of revenue, up from 1.0% a year earlier.

Revenue contracted 27.6% year‑over‑year to $76.4 million, reflecting a steep decline in the number of independent coaches. Despite the revenue dip, average revenue per coach surged 41.0% to $6,529, underscoring a shift toward higher‑margin, productivity‑focused operations. The earnings surprise and coach‑level gains together paint a mixed picture for investors weighing short‑term pain against potential long‑term upside.

Revenue and Coach Dynamics

The company’s active earning coach count fell 48.7% to 11,700, down from 22,800 in the comparable period a year earlier, driven by intensified competition from GLP‑1 weight‑loss medications and a tougher client‑acquisition environment. Yet the remaining coach base generated markedly higher sales, lifting revenue per coach to $6,529 versus $4,630 a year ago. Higher per‑coach earnings indicate a more efficient network, but the continued erosion of the coach base could constrain growth if not reversed.

Cost Structure and Margin Pressure

Gross profit declined 30.3% to $53.4 million, with the gross margin slipping to 69.9% from 72.6% a year earlier. Selling, general, and administrative expenses fell 25.7% to $57.7 million, yet rose to 75.6% of revenue, up 200 basis points year‑over‑year, as fixed‑cost leverage eroded. The operating loss widened to $4.3 million, representing 5.7% of revenue compared with 1.0% previously, reflecting both lower sales volumes and higher expense intensity.

While cost cuts have improved headline expense figures, the loss of scale magnifies the impact of fixed costs, suggesting that further margin recovery will depend on rebuilding top‑line momentum alongside continued expense discipline.

Market Reaction and Investor Sentiment

The earnings beat helped lift the stock, yet the pronounced revenue decline and operating loss keep the ticker under pressure. Investors are weighing the upside of a 41% rise in per‑coach revenue against the risk that a shrinking coach network may limit future scale, a balance that will likely influence pricing in the coming weeks.

Outlook and Upcoming Catalysts

Management forecast third‑quarter revenue between $60 million and $80 million, with a loss per share expected to range from $0.15 to $0.65, excluding one‑time Catalyst program costs. Full‑year revenue guidance sits at $270 million to $300 million, with loss per share projected between $0.25 and $1.75.

Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.